LFCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lifecore Biomedical Inc (LFCR) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has positive long-term catalysts and improving revenue growth, the current technical indicators, lack of strong trading signals, and short-term bearish trends suggest waiting for a better entry point.
The stock is currently in a bearish trend with the MACD histogram below 0 and negatively contracting. The RSI indicates the stock is oversold at 14.953, but moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 3.888), which could act as a floor, but the overall trend remains weak.
The company has signed two CDMO manufacturing service agreements expected to enhance market competitiveness and contribute to 2028 commercial revenue. Revenue increased by 25.92% YoY in Q1 2026, and gross margin improved significantly by 43.83% YoY.
Net income dropped by -32.76% YoY, and EPS remains negative. Analysts have lowered price targets due to a softer FY26 outlook, with commercial ramps delayed. Short-term stock trend analysis suggests potential for further downside in the next week and month.
In Q1 2026, Lifecore's revenue increased by 25.92% YoY to $31.1M, and gross margin improved by 43.83% YoY to 31.37%. However, net income dropped to -$10.91M (-32.76% YoY), and EPS remains negative at -0.54, showing mixed financial performance.
Analysts have mixed views. Barrington upgraded the stock to Outperform with a $5.50 price target, citing long-term value creation. However, Stephens lowered the price target to $5 from $8.50, citing a softer FY26 outlook as a timing issue rather than a long-term concern.
